IP Library Granted Patent US 12,673,973
Granted Patent B2
US 12,673,973 · App. 18/285,543 · Granted Jul 7, 2026

Peptide having blood coagulation activity, and use thereof

Inventors: Yong Ji Chung (Anyang-si, KR); Eun Mi Kim (Anyang-si, KR); Mihee Cho (Anyang-si, KR); Kyeongnan Kwon (Anyang-si, KR)
Assignee: CAREGEN CO, LTD.
C07K7/08A61K33/06A61K38/10A61P7/04A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,673,973
App. No.
18/285,543
Filed
Oct 4, 2023
Granted
Jul 7, 2026
Kind
B2
Art Unit
1654
USPC
514/13.7
Abstract

The present invention relates to a peptide, of a novel sequence, characterized by being gelled in accordance with the pH condition. Since the peptide may induce blood coagulation, a composition comprising the peptide can be utilized for the use of inducing hemostasis.

Claims (11)

1 . A peptide having pH-dependent gelation property, which comprises the amino acid sequence of SEQ ID NO: 1.

2 . The peptide according to claim 1 , wherein the peptide gelates at pH 4 to pH 8.

3 . The peptide according to claim 1 , wherein the peptide can induce blood coagulation.

4 . A composition for inducing hemostasis, comprising the peptide of claim 1 .

5 . The composition for inducing hemostasis according to claim 4 , wherein the peptide is contained in the composition at a concentration of 0.5 mg/ml to 50 mg/ml.

6 . The composition for inducing hemostasis according to claim 4 , wherein the composition further comprises calcium ions.

7 . The composition for inducing hemostasis according to claim 4 , wherein the composition coagulates blood at pH 4 to pH 8.

8 . The composition for inducing hemostasis according to claim 4 , wherein the composition coagulates blood under the condition that the salt concentration is 50 mM or more.

9 . The composition for inducing hemostasis according to claim 4 , wherein the composition does not cause hemolysis.

10 . The composition for inducing hemostasis according to claim 4 , wherein the composition is in the form of at least one selected from the group consisting of powder formulations, patches, gauze, sprays and injections.

11 . A method for hemostasis comprising the step of treating the composition of claim 4 to a bleeding site of an animal in which bleeding occurs.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2023
From: CHUNG, YONG JI; KIM, EUN MI; CHO, MIHEE; KWON, KYEONGNAN
To: CAREGEN CO., LTD
Reel/Frame 065129/0892 →
Priority Claims (1)
KR 10-2021-0058155 · May 4, 2021 · national
Continuity (1)
Related Publication 20240368222A1 · Nov 7, 2024
References Cited (33)
US 11124540B2 · Forssmann · 2021 [cited by applicant]
US 11602539B2 · Kim et al. · 2023 [cited by applicant]
US 20060025524A1 · Schneider et al. · 2006 [cited by applicant]
US 20110165200A1 · Schneider et al. · 2011 [cited by applicant]
US 20160015855A1 · Nohara et al. · 2016 [cited by applicant]
US 20160362451A1 · Gil et al. · 2016 [cited by applicant]
US 20190201436A1 · Kim et al. · 2019 [cited by applicant]
US 20190248920A1 · Schmidt et al. · 2019 [cited by applicant]
US 20200164100A1 · Nohara et al. · 2020 [cited by applicant]
US 20200247850A1 · Forssmann · 2020 [cited by applicant]
US 20200399310A1 · Gil et al. · 2020 [cited by applicant]
US 20210268071A1 · Pestel et al. · 2021 [cited by applicant]
US 20220033442A1 · Gil et al. · 2022 [cited by applicant]
US 20220089778A1 · Schmidt et al. · 2022 [cited by applicant]
CN 111094320A · 2020 [cited by applicant]
JP 2008508292A1 · 2008 [cited by applicant]
JP 2015142720A · 2015 [cited by applicant]
JP 2017510568A · 2017 [cited by applicant]
JP 2020533023A · 2020 [cited by applicant]
KR 1020010049671A · 2001 [cited by applicant]
KR 1020150126394A · 2015 [cited by applicant]
KR 1020180027126A · 2018 [cited by applicant]
KR 1020190052027A · 2019 [cited by applicant]
KR 1020190073576A · 2019 [cited by applicant]
KR 1020190102101A · 2019 [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for International Patent Application No. PCT/KR2022/0050900 mailed Jul. 15, 2022 (15 pages including English Translation of ISR). [cited by applicant]
Notice of Allowance issued on Mar. 7, 2024 for the corresponding Korean patent application Application No. 10-2021-0058155 (10 pages including English Translation). [cited by applicant]
First Office Action issued on Jun. 24, 2025 for the corresponding Chinese patent application Application No. 202280031584.1 (10 pgs including English Translation). [cited by applicant]
First Office Action issued on Oct. 8, 2024 for corresponding Japanese Application No. 2023-560412 (5 pages). [cited by applicant]
Wei Shuda, et al., “Self-assembling RATEA16 peptide nanofiber designed for rapid hemostasis”, Journal of Materials Chemistry B, 2020, vol. 8, No. 9, pp. 1897-1905. [cited by applicant]
Extended European Search Report dated Oct. 10, 2024 for EP Application No. 22799008.2 (9 pages). [cited by applicant]
Carter Tiffany, et al., “Self-Assembling Peptide Solution Accelerates Hemostasis”, Advances in Wound Care, 2021, vol. 10, No. 4, pp. 191-203. [cited by applicant]
Huang Lu-Chieh, et al., “Bioinspired Self-assembling Peptide Hydrogel with Proteoglycan-assisted Growth Factor Delivery for Therapeutic Angiogenesis”, Theranostics, 2019, vol. 9, No. 23, pp. 7072-7087. [cited by applicant]